North America’s medical devices industry saw a drop of 7.48% in deal activity during January 2022, when compared with the last 12-month average, led by Owens & Minor’s $1.6bn acquisition of Apria, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 99 medical devices industry deals worth $4.7bn were announced for the region in January 2022, against the 12-month average of 107 deals.
Of all the deal types, venture financing saw most activity in January 2022 with 57 transactions, representing a 57.6% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 33 deals, followed by private equity deals with nine transactions, respectively capturing a 33.3% and 9.1% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $3.27bn, while venture financing and private equity deals totalled $1.17bn and $250m, respectively.
North America medical devices industry deals in January 2022: Top deals
The top five medical devices deals accounted for 67.4% of the overall value during January 2022.
The combined value of the top five medical devices deals stood at $3.16bn, against the overall value of $4.7bn recorded for the month.
The top five medical devices industry deals of January 2022 tracked by GlobalData were:
1) Owens & Minor $1.6bn acquisition deal with Apria
2) The $623m acquisition of GeneDX by Sema4 OpCo
3) ConvaTec Group $450m acquisition deal with Triad Life Sciences
4) The $250m private equity of Fluidigm by Casdin Capital and Viking Global Investors
5) Maravai LifeSciences Holdings $240m acquisition deal with MyChem
